Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Long-term outcomes and significance of preoperative lymphocyte-to-monocyte ratio as a prognostic indicator in patients with invasive pancreatic neoplasms after repeat pancreatectomy

Fig. 4

Cause-specific survival after repeat pancreatectomy in patients with invasive pancreatic neoplasms. a The Kaplan–Meier analysis of cancer-specific survival after repeat pancreatectomy in patients with invasive pancreatic neoplasms. The median cancer-specific survival time of patients with invasive pancreatic neoplasms was 61 months for patients who underwent repeat pancreatectomy, and 8 months for patients who received chemotherapy only (P < 0.0001, log-rank test). b The Kaplan–Meier analysis of cancer-specific survival after repeat pancreatectomy in patients with invasive IPMC, PDAC, and PACC. c The Kaplan–Meier analysis of cancer-specific survival after repeat pancreatectomy in patients with LMR ≥ 3.3 compared to that in patients with LMR <  3.3 (P = 0.0098, log-rank test). No significant difference on survival was observed in patients with LMR <  3.3 compared to patients who received chemotherapy only (P = 0.092, log-rank test)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us